Search results :

Gadoteridol

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: V08CA04

Side effects

Options: Hide MedDRA Preferred Terms

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3
Dysgeusia Dysgeusia 1.43% x x x
Nausea Nausea 1.43% x x x
Headache Headache 0.68% x x x
Paraesthesia Paraesthesia 0.42% x x x
Tingling sensation 0.08% x x x
Hypotension Hypotension 0.34% x x x
Vomiting Vomiting 0.34% x x x
Injection site pain Injection site pain 0.34% x x x
Dizziness Dizziness 0.25% x x x
Syncope 0.08% x x x
Dry mouth Dry mouth 0.25% x x x
Anxiety Anxiety 0.17% x x x
Dermatitis Rash 0.17% x x x
Rash Rash 0.17% x x x
Flushing Flushing 0.17% x x x
Gingivitis Gingivitis 0.17% x x x
Pruritus Pruritus 0.08% - 0.25% x x x
Rhinitis Rhinitis 0.17% x x x
Urticaria Urticaria 0.17% x x x
Lacrimation increased Tearing eyes 0.17% x x x
Abdominal pain Abdominal cramps 0.08% x x x
Chest pain Chest pain 0.08% x x x
Cough Cough 0.08% x x x
Dyspnoea Dyspnoea 0.08% x x x
Body temperature increased Body temperature increased 0.08% x x x
Shock Syncope 0.08% x x x
Syncope Syncope 0.08% x x x
Loss of consciousness Syncope 0.08% x x x
Loss of consciousness postmarketing x x x
Tinnitus Tinnitus 0.08% x x x
Erythema Erythema 0.08% x
Musculoskeletal stiffness Neck stiffness 0.08% x x x
Nuchal rigidity Neck stiffness 0.08% x x x
Tongue disorder Tongue oedema 0.08% x
Tongue oedema Tongue oedema 0.08% x
Nodal rhythm Nodal rhythm 0.08% x x x
Staring Staring 0.08% x x x
Rash maculo-papular Rash maculo-papular 0.08% x
Face oedema Face oedema 0.08% x x x
Electrocardiogram PR prolongation Electrocardiogram PR prolongation 0.08% x x x
Diarrhoea Loose stools 0.08% x x x
Apnoea Apnoea postmarketing x x x
Cardiovascular disorder Cardiovascular disorder postmarketing x x x
Cyanosis Cyanosis postmarketing x x x
Dysphagia Dysphagia postmarketing x x x
Cardiac arrest Cardiac arrest postmarketing x x x
Hypertension Hypertension postmarketing x x x
Laryngeal oedema Laryngeal oedema postmarketing x x x
Salivary hypersecretion Salivary hypersecretion postmarketing x x x
Hyperhidrosis Sweating postmarketing x x x
Tremor Tremor postmarketing x x x
Urinary incontinence Urinary incontinence postmarketing x x x
Wheezing Wheezing postmarketing x x x
Stupor Stupor postmarketing x x x
Depressed level of consciousness Stupor postmarketing x x x
Deafness transitory Deafness transitory postmarketing x x x
Generalised oedema Generalised oedema postmarketing x x x
Fluid retention Generalised oedema postmarketing x x x
Malaise Malaise postmarketing x x x
Discomfort Malaise postmarketing x x x
Feeling abnormal Malaise postmarketing x x x
Ill-defined disorder Malaise postmarketing x x x
Anaphylactic shock Anaphylactoid reaction postmarketing x x x
Anaphylactoid reaction Anaphylactoid reaction postmarketing x x x
Bradycardia Bradycardia postmarketing x x x
Oedema Oedema x x
Hypersensitivity Hypersensitivity x
Laryngospasm Laryngospasm x x
Pain Pain x x
Convulsion Convulsion x x x
Injection site reaction Injection site reaction x x
Rash macular Rash macular x x
Nephrogenic systemic fibrosis Nephrogenic systemic fibrosis x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

GADOTERIDOL / PROHANCE - LIQ IV 279.3MG/ML

Side effects:55
Source:Health Canada

GADOTERIDOL / PROHANCE MULTIPACK

Side effects:56
Source:FDA

gadoteridol

Side effects:58
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label